Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.86 (HKD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 38.419 | 39.255 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 711.362 | 15.014 | 475.643 | 66.267 | 0 | 0 |
| Gross Profit
| -672.943 | 24.241 | -475.643 | -66.267 | 0 | 0 |
| Gross Profit Ratio
| -17.516 | 0.618 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 183.387 | 649.885 | 1,465.324 | 1,826.301 | 228.219 | 45.799 |
| General & Administrative Expenses
| 20.39 | 52.474 | 113.07 | 345.71 | 76.429 | 17.035 |
| Selling & Marketing Expenses
| 19.705 | 54.766 | 0 | 0 | 0 | 0 |
| SG&A
| 40.095 | 107.24 | 113.07 | 345.71 | 76.429 | 17.035 |
| Other Expenses
| 0 | -732.884 | 282.758 | -14.226 | -20.359 | -15.909 |
| Operating Expenses
| 263.504 | 24.241 | 1,861.152 | 2,157.785 | 284.289 | 46.925 |
| Operating Income
| -951.207 | -144.402 | -2,446.202 | -6,014.691 | -909.925 | -38.251 |
| Operating Income Ratio
| -24.759 | -3.679 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 47.779 | 5.863 | -100.699 | -3,778.025 | -608.25 | -10.332 |
| Income Before Tax
| -903.428 | -138.539 | -2,451.903 | -6,016.303 | -912.898 | -48.583 |
| Income Before Tax Ratio
| -23.515 | -3.529 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.229 | 1.612 | 2.973 | 10.332 |
| Net Income
| -903.428 | -138.539 | -2,451.674 | -6,017.915 | -915.871 | -58.915 |
| Net Income Ratio
| -23.515 | -3.529 | 0 | 0 | 0 | 0 |
| EPS
| -0.72 | -0.11 | -2.22 | -5.37 | -0.79 | -0.051 |
| EPS Diluted
| -0.72 | -0.11 | -2.22 | -5.36 | -0.79 | -0.051 |
| EBITDA
| -916.54 | -45.074 | -2,386.108 | -2,226.417 | -335.041 | -61.761 |
| EBITDA Ratio
| -23.856 | -1.148 | 0 | 0 | 0 | 0 |